The contribution of PD-1 blockade on NK cells in immunotherapy has been demonstrated in several mouse models of cancer, where PD-1 engagement by PD-L1+ tumor cells could strongly suppress NK cell–mediated anti-tumor immunity (79). This evidence concerns the gene CD274 and neoplasm.